pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

Enterome is a clinical stage company, pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

LOCATION

  • Paris, , France

  • Évry-Courcouronnes,, None, France

    • THERAPEUTIC AREAS

  • Immunology

  • Inflammatory Disease

  • Oncology

    • WEBSITE

    https://www.enterome.com

    CAREER WEBSITE

    https://www.enterome.com/#careers

    SOCIAL MEDIA

    INVESTORS

    bms health-for-life-capital inra-transfert lundbeckfonden lundbeckfonden nestle-health-science omnes-capital principia-scr seventure-partners takeda

    PRESS RELEASES


    Dec 12, 2022

    Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma


    Dec 7, 2022

    Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022


    Nov 16, 2022

    Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022


    Nov 10, 2022

    Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma


    Nov 7, 2022

    Enterome to present updated safety, immunogenicity and efficacy data from its Phase 1/2 trial of EO2401 in recurrent glioblastoma (ROSALIE study) at SITC 2022


    For More Press Releases
    Google Analytics Alternative